Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients

Felipe Kazmirczak, Prabhjot S. Nijjar, Lei Zhang, Andrew Hughes, Ko-Hsuan Amy Chen, Osama Okasha, Cindy M. Martin, Mehmet Akçakaya, Afshin Farzaneh-Far and Chetan Shenoy

Abstract

Background: There is a critical need for non-invasive methods to detect coronary allograft vasculopathy and to risk stratify heart transplant recipients. Vasodilator stress testing using cardiovascular magnetic resonance imaging (CMR) is a promising technique for this purpose. We aimed to evaluate the safety and the prognostic value of regadenoson stress CMR in heart transplant recipients.

Methods: To evaluate the safety, we assessed adverse effects in a retrospective matched cohort study of consecutive heart transplant recipients who underwent regadenoson stress CMR matched in a 2:1 ratio to age- and gender-matched non-heart transplant patients. To evaluate the prognostic value, we compared the outcomes of patients with abnormal vs. normal regadenoson stress CMRs using a composite endpoint of myocardial infarction, percutaneous intervention, cardiac hospitalization, retransplantation or death.

Results: For the safety analysis, 234 regadenoson stress CMR studies were included - 78 performed in 57 heart transplant recipients and 156 performed in non-heart transplant patients. Those in heart transplant recipients were performed at a median of 2.74 years after transplantation. Thirty-four (44%) CMR studies were performed in the first two years after heart transplantation. There were no differences in the rates of adverse effects between heart transplant recipients and non-heart transplant patients. To study the prognostic value of regadenoson stress CMRs, 20 heart transplant recipients with abnormal regadenoson stress CMRs were compared to 37 with normal regadenoson stress CMRs. An abnormal regadenoson stress CMR was associated with a significantly higher incidence of the composite endpoint compared with a normal regadenoson stress CMR (3-year cumulative incidence estimates of 32.1% vs. 12.7%, \( p = 0.034 \)).

Conclusions: Regadenoson stress CMR is safe and well tolerated in heart transplant recipients, with no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation. An abnormal regadenoson stress CMR identifies heart transplant recipients at a higher risk for major adverse cardiovascular events.

Keywords: Cardiovascular magnetic resonance, Stress perfusion, Vasodilator, Regadenoson, Safety

Correspondence: cshenoy@umn.edu

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Heart transplantation is a proven life-saving treatment option for patients with end-stage heart failure. Despite many advances in the field, graft failure and cardiac allograft vasculopathy (CAV) continue to represent significant causes of morbidity and mortality [1]. Early detection of CAV may allow changes in medical therapy and prevention of progression. However, early diagnosis is challenging due to either absent or atypical symptoms related to allograft denervation [2, 3]. This has necessitated routine screening of heart transplant recipients for CAV. Current preferred methods for surveillance involve coronary angiography and intravascular ultrasound. However, these methods expose patients to the risks of an invasive procedure and involves the use of iodinated contrast with its associated risk of kidney injury. This is a particularly important issue since chronic kidney disease is common in these patients. Thus, there is a critical need for noninvasive techniques to assess cardiac allograft function and to detect treatable CAV [4, 5].

Vasodilator stress testing by cardiovascular magnetic resonance imaging (CMR) is a promising technique for the detection of CAV and for the risk stratification of heart transplant recipients. The use of this technique has been limited because adenosine has been associated with super-sensitivity of the denervated sinus and atrioventricular nodes after heart transplantation, resulting in exaggerated sinus node and atrioventricular node suppression [6, 7].

Regadenoson is a newer selective A2A adenosine receptor agonist used for vasodilator stress testing. Studies in non-transplant patients have shown no incidence of high-degree atrioventricular block with regadenoson [8–10] in contrast to a 4–5% incidence with a six-minute infusion of adenosine [11]. This raises the possibility that regadenoson may be safe in heart transplant recipients. However, heart transplant recipients were excluded from all pre-approval studies of regadenoson [8, 12, 13]. Thus, there are a paucity of data on the safety and tolerability of regadenoson in heart transplant recipients. There are also no data on the safety of regadenoson early after transplantation, or on its prognostic value in heart transplant recipients. Accordingly, we aimed to evaluate the safety and the prognostic value of regadenoson stress CMR in heart transplant recipients.

Methods
Patients
We identified consecutive heart transplant recipients undergoing regadenoson stress CMR performed on at the University of Minnesota Medical Center, Minneapolis, Minnesota, USA between April 2012 and December 2017. For the safety analysis, these regadenoson stress CMRs were matched by patient age and gender in a 2:1 ratio to comparison regadenoson stress CMRs performed in non-heart transplant patients during the same time period. All stress CMRs were identified from the University of Minnesota Cardiovascular Magnetic Resonance Registry, an ongoing observational registry including all patients that undergo CMR at the University of Minnesota [14]. This study was approved by University of Minnesota’s Institutional Review Board with a waiver of informed consent.

CMR protocol, and assessment of symptoms and adverse effects
Regadenoson stress CMRs were performed using a 1.5 T scanner (Siemens Aera, Siemens Healthineers, Erlangen, Germany) with phased-array coil systems. All patients underwent a CMR protocol consisting of: 1) cine CMR at rest for assessment of left ventricular (LV) function; 2) gadolinium first-pass perfusion imaging 1–2 min after regadenoson injection for assessment of stress perfusion; 3) gadolinium first-pass perfusion imaging without regadenoson for assessment of rest perfusion; and 4) late gadolinium enhancement (LGE) CMR 10–15 min later. Typically, the procedure was completed in 45 min. Patients were asked to refrain from caffeine for 24 h before the regadenoson stress CMR. Patients with pre-existing second- or third-degree atrioventricular block or sinus node dysfunction were excluded. After cine CMR, the patient table was partially pulled outside the scanner bore to allow access to the patient for regadenoson administration. Regadenoson 0.4 mg (Astellas, Northbrook, Illinois, USA) was injected over approximately 10 s into a peripheral vein followed by a 5 mL saline flush. The patient was centered back into the scanner and the perfusion sequence was started within 1–2 min of regadenoson injection. Gadolinium-based contrast (0.075 mmol/kg gadobenate dimeglumine, Bracco Imaging or 0.1 mmol/kg gadobutrol, Bayer HealthCare LLC, Milan, Italy) was infused at 4–5 mL/s followed by a saline flush (50 mL) via an antecubital vein for both stress and rest perfusion. All patients were monitored by CMR-compatible, three-lead wireless continuous electrocardiogram (ECG) system and pulse oximetry during the study. Blood pressure was monitored before and after regadenoson administration, and a 12-lead ECG was performed before and after the study. Prior to April 2014, aminophylline was used for significant patient symptoms. All studies performed after April 2014 routinely received aminophylline 100 mg intravenously for reversal of hyperemia after stress images were acquired [15]. Patients were routinely asked about their symptoms before and after regadenoson administration and aminophylline administration. Stress-related adverse events including death, myocardial infarction, ventricular tachycardia, ventricular fibrillation, hospitalization, bronchospasm, and non-life-threatening arrhythmias were noted in the electronic medical record.
by trained nurses. For this study, data on arrhythmias were extracted from the ECGs and the nurse notes.

**CMR analyses**
All stress CMR exams were interpreted blinded to patient outcomes by a consensus of two CMR physicians with > 10 (C. S.) and 2 (F. K.) years of experience respectively. Perfusion and LGE images were assessed in a qualitative fashion. A perfusion defect was identified as a regional dark area that: 1) persisted for > 2 beats while other regions enhanced during the first-pass of contrast through the LV myocardium; and 2) involved the subendocardium. LV systolic dysfunction was defined as an abnormality in global or regional systolic function on cine imaging. Ischemia was defined as a segmental stress perfusion defect without matching hyperenhancement (same location and size) on LGE imaging. A match between a perfusion defect and hyperenhancement on LGE was considered as fibrosis without ischemia. As in routine clinical practice, systolic dysfunction, ischemia and LGE images were interpreted in a binary fashion as normal or abnormal. A normal regadenoson stress CMR was defined as normal global and regional LV systolic function, no ischemia and no fibrosis.

**Assessment of clinical outcomes**
Follow up data were collected through review of patient medical records from all locations within our institution’s health system. Mortality status and death dates were also cross-referenced with data from the Minnesota Department of Health’s Office of Vital Records. Collected outcomes included: myocardial infarction, percutaneous intervention, cardiac hospitalization, retransplantation and death. These events together formed the composite endpoint of major adverse cardiovascular events.

**Statistics**
Continuous variables were expressed as means and standard deviations, or medians and inter-quartile ranges (IQR) for data that were not normally distributed. Regadenoson stress CMR in the heart transplant recipient and comparison groups were compared using generalized estimating equations in the form of linear regression or logistic regression, as appropriate. Prognostic endpoints were compared using Kaplan-Meier survival analyses and log rank testing. All tests were two-tailed. A p of < 0.05 was used to denote statistical significance. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina, USA).

**Results**

**Patients**
In the study group, 78 regadenoson stress CMRs were performed in 57 unique heart transplant recipients at a median of 2.74 (interquartile range 1.02–7.25) years after transplantation. Thirty-four (44%) CMRs were performed in the first two years after heart transplantation.

Forty-one patients had one, 12 patients had two, three patients had three, and one patient had four regadenoson stress CMRs each. In the comparison group, only one instance of regadenoson stress CMR was included per patient. Patient characteristics are summarized in Table 1. Compared to the heart transplant recipient group, the comparison group had higher rates hyperlipidemia, tobacco use, prior myocardial infarction, and chronic obstructive lung disease.

**Baseline ECG characteristics**
Baseline electrocardiographic (ECG) characteristics are listed in Table 2. In the heart transplant recipient group, there were no instances of patients with pre-existing sinus node dysfunction or atrioventricular block of any degree. In 24 (31%) instances, patients had a right bundle branch block, which was significantly higher than in the comparison group. In 47 (60%) instances, they had ST-T abnormalities.

**Hemodynamic changes**
In the heart transplant recipient group, the mean heart rate increased from 92 ± 11 bpm to 107 ± 12 bpm, while it increased from 73 ± 15 bpm to 100 ± 13 bpm in the comparison group. There were no significant changes in pre- and post-stress blood pressures in both the heart transplant recipient and comparison groups (Table 3).

**Adverse effects**
All regadenoson stress CMRs were completed in both heart transplant recipient and comparison groups. Adverse effects are listed in Table 4. One stress CMR in a heart transplant recipient had to be temporarily interrupted due to regadenoson-related abdominal cramps; the patient received a second dose of regadenoson after 20 min without any further symptoms. Side-effects requiring an intervention occurred in two patients (3%) in the heart transplant recipient group – one had chest pain requiring nitroglycerin and one had symptomatic hypotension requiring intravenous fluids – and in one patient (0.6%) in the comparison group that had symptomatic hypotension requiring intravenous fluids (p = 0.26). In all three cases, the symptoms resolved with treatment and the patients were discharged home after the regadenoson stress CMR. Minor side-effects not requiring any interventions such as dyspnea, nausea and headache occurred at similar rates in both groups. There were no occurrences of death, asystole, sinus pause, sinus arrest, high-degree atrioventricular block, ventricular arrhythmias, stress-induced atrial fibrillation, or myocardial infarction. No patients required hospitalization or emergency room evaluation.
### Table 1 Patient characteristics

| Patient characteristic | Heart transplant recipients (n = 78) | Non-transplant patients (n = 156) | p value |
|------------------------|--------------------------------------|-----------------------------------|---------|
| Age, years (median, IQR) | 50.1 (30.5–61.2) | 50.1 (30.9–61.2) | 0.01 |
| Male, n (%) | 30 (38) | 60 (38) | 1.00 |
| Body mass index, kg/m² (median, IQR) | 29.0 (24.1–31.9) | 29.1 (23.8–34.2) | 0.10 |
| Graft age, years (median, IQR) | 2.74 (1.02–7.25) | N/A | N/A |
| Rejection, Grade > 3 ever, n (%) | 19 (24.4) | N/A | N/A |
| Hypertension, n (%) | 42 (54) | 80 (51) | 0.67 |
| Diabetes mellitus, n (%) | 19 (24) | 27 (17) | 0.20 |
| Hyperlipidemia, n (%) | 75 (96) | 67 (43) | < 0.001 |
| Current tobacco use, n (%) | 1 (1) | 16 (10) | 0.003 |
| Myocardial infarction⁵, n (%) | 3 (4) | 25 (16) | 0.004 |
| Percutaneous intervention⁵, n (%) | 9 (12) | 19 (12) | 0.89 |
| Coronary artery bypass graft⁵, n (%) | 0 | 8 (5) | 0.06 |
| Atrial fibrillation⁵, n (%) | 5 (6) | 8 (5) | 0.71 |
| Cerebrovascular accident, n (%) | 10 (13) | 10 (6) | 0.09 |
| Chronic obstructive lung disease, n (%) | 6 (8) | 29 (19) | 0.02 |
| Serum creatinine, mg/dL (± SD) | 1.12 (0.36) | 0.87 (0.20) | < 0.001 |

**Medications**

| Medication | Heart transplant recipients (n = 78) | Non-transplant patients (n = 156) | p value |
|------------|--------------------------------------|-----------------------------------|---------|
| Angiotensin converting enzyme-inhibitor, n (%) | 15 (19) | 46 (29) | 0.06 |
| Angiotensin receptor blocker, n (%) | 17 (22) | 21 (13) | 0.14 |
| Beta-blocker, n (%) | 10 (13) | 65 (42) | < 0.001 |
| Calcium channel blocker, n (%) | 18 (23) | 19 (12) | 0.04 |
| Aspirin, n (%) | 72 (92) | 59 (38) | < 0.001 |
| ADP/P2Y12 inhibitor, n (%) | 7 (9) | 13 (8) | 0.87 |
| Statin, n (%) | 72 (92) | 53 (34) | < 0.001 |
| Glucocorticoid, n (%) | 14 (18) | N/A | N/A |
| Purine inhibitor, n (%) | 72 (92) | N/A | N/A |
| Calcineurin inhibitor, n (%) | 66 (85) | N/A | N/A |
| mTOR inhibitor, n (%) | 18 (23) | N/A | N/A |

*IQR Interquartile Range, SD Standard Deviation; ⁵denotes events after heart transplantation in the heart transplant group*

### Table 2 Baseline ECG findings

| ECG finding | Heart transplant recipients (n = 78) | Non-transplant patients (n = 156) | p value |
|-------------|--------------------------------------|-----------------------------------|---------|
| Sinus rhythm with no abnormalities, n (%) | 19 (24) | 49 (31) | 0.26 |
| First degree atrioventricular block, n (%) | 0 | 6 (4) | 0.18 |
| Left bundle branch block, n (%) | 0 | 0 | N/A |
| Right bundle branch block, n (%) | 24 (31) | 8 (5) | < 0.001 |
| Atrial fibrillation/flutter, n (%) | 1 (1) | 4 (3) | 0.48 |
| Premature atrial complexes, n (%) | 1 (1) | 4 (3) | 0.48 |
| Premature ventricular complexes, n (%) | 1 (1) | 9 (6) | 0.07 |
| ST-T abnormalities, n (%) | 47 (60) | 104 (67) | 0.33 |
Clinical outcomes
Among 57 heart transplant recipients, 20 had an abnormal regadenoson stress CMRs while 37 had normal testing. Example images of heart transplant recipients from the study are provided in Fig. 1. At a median follow up of 1.3 years (interquartile range 0.5–2.1 years), there were no instances of myocardial infarction, four percutaneous coronary interventions, four cardiac hospitalizations, three retransplantations, and four deaths, accounting for 10 composite outcomes. On Kaplan-Meier analyses, the cumulative incidence estimates were significantly different between patients with abnormal regadenoson stress CMRs and those with normal regadenoson stress CMRs (3-year cumulative incidence estimates of 32.1% vs. 12.7%, \( p = 0.034 \); Fig. 2). Due to the small number of events, multivariable analysis was not performed.

Discussion
Among heart transplant recipients undergoing regadenoson stress CMR, we found low and similar rates of adverse effects as in non-transplant patients. Importantly, we found no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation. There were no serious adverse effects. Unlike adenosine, regadenoson appears to be a safe vasodilator stress agent for use after heart transplantation. An abnormal regadenoson stress CMR was associated with a significantly higher incidence of the composite endpoint of major adverse cardiovascular events compared with a normal regadenoson stress CMR.

Our safety findings confirm findings from a prior smaller study of patients undergoing single-photon emission computed tomography (SPECT) stress testing. In 40 recipients at a mean of 9.8 ± 4.5 years after heart transplantation, Cavalcante et al. noted one instance of sinus pause and no atrioventricular block [16]. The same recipients previously had adenosine SPECT and experienced five episodes of second-degree, Mobitz type II atrioventricular block and three episodes of sinus pauses.

Table 3 Hemodynamic findings

| Hemodynamic finding                          | Heart transplant recipients (n = 78) | Non-transplant patients (n = 156) | \( p \) value |
|---------------------------------------------|-------------------------------------|----------------------------------|--------------|
| Pre-stress heart rate, bpm (± SD)           | 92 (11)                             | 73 (15)                          | < 0.001      |
| Pre-stress systolic blood pressure, mm Hg (± SD) | 124 (18)                           | 127 (19)                         | 0.27         |
| Pre-stress diastolic blood pressure, mm Hg (± SD) | 80 (13)                            | 78 (13)                          | 0.21         |
| Peak heart rate, bpm (± SD)                 | 107 (12)                            | 100 (13)                         | < 0.001      |
| Post-stress heart rate, bpm (± SD)          | 95 (12)                             | 74 (16)                          | < 0.001      |
| Post-stress systolic blood pressure, mm Hg (± SD) | 124 (21)                           | 126 (19)                         | 0.64         |
| Post-stress diastolic blood pressure, mm Hg (± SD) | 81 (13)                            | 76 (13)                          | 0.01         |

Table 4 Adverse effects

| Adverse effect                                      | Heart transplant recipients (n = 78) | Non-transplant patients (n = 156) | \( p \) value |
|-----------------------------------------------------|-------------------------------------|----------------------------------|--------------|
| Death, n (%)                                        | 0                                   | 0                                | N/A          |
| Asystole, n (%)                                     | 0                                   | 0                                | N/A          |
| Sinus pause or arrest, n (%)                        | 0                                   | 0                                | N/A          |
| High-grade atrioventricular block, n (%)            | 0                                   | 0                                | N/A          |
| Ventricular tachycardia or ventricular fibrillation, n (%) | 0                                   | 0                                | N/A          |
| Atrial fibrillation, n (%)                          | 0                                   | 0                                | N/A          |
| Chest pain requiring sublingual nitroglycerin, n (%) | 1 (1)                               | 0                                | 0.33         |
| Myocardial infarction, n (%)                        | 0                                   | 0                                | N/A          |
| Symptomatic hypotension, n (%)                      | 1 (1)                               | 1 (0.6)                          | 0.65         |
| Dyspnea, n (%)                                      | 6 (7)                               | 9 (6)                            | 0.58         |
| Nausea, n (%)                                       | 6 (7)                               | 3 (2)                            | 0.08         |
| Headache, n (%)                                     | 2 (3)                               | 0                                | 0.11         |
| Allergic reaction (rash, hives, etc.), n (%)        | 0                                   | 0                                | N/A          |
| Contrast extravasation, n (%)                       | 0                                   | 2 (1)                            | 0.55         |
| Thrombophlebitis, n (%)                             | 0                                   | 0                                | N/A          |
| Hospitalization, n (%)                              | 0                                   | 0                                | N/A          |

SD Standard Deviation
Sympathetic reinnervation most often occurs after 18 months and parasympathetic reinnervation most often occurs at around two years after heart transplantation [3]. Since super-sensitivity to adenosine is related to denervation, the exaggerated sinus node and atrioventricular node suppression may be higher early after heart transplantation [17]. With 44% of studies performed in the first two years after heart transplantation, our findings demonstrate, for the first time, that regadenoson is safe also early after heart transplantation when recipients may be more vulnerable to super-sensitivity.

| Cine (End-diastolic) | Cine (End-systolic) | Stress Perfusion | LGE | Safety | Outcome |
|----------------------|---------------------|-----------------|-----|--------|---------|
| A                    |                     |                 |     |        |         |
| B                    |                     |                 |     |        |         |

**Fig. 1** Example images of heart transplant recipients from the study. Panel a shows a patient with a decreased left ventricular (LV) ejection fraction of 41% and ischemia in multiple coronary artery territories without late gadolinium enhancement. The patient had no adverse effects from the stress CMR and on follow-up underwent multiple percutaneous interventions and eventually a retransplantation. Panel b shows a patient with a normal LV ejection fraction of 55%, no ischemia and no late gadolinium enhancement. The patient had no adverse effects from the stress CMR and on follow-up had no events.

| A | Abnormal CMR (n = 20) | Normal CMR (n = 37) |
|---|------------------------|----------------------|
| Composite endpoint (n = 10) | 6 (30%) | 4 (11%) |
| No composite endpoint (n = 47) | 14 (70%) | 33 (89%) |

**Fig. 2** Incidence of composite endpoints according to abnormal vs. normal regadenoson stress CMRs. Panel a outlines the rates of the composite endpoint according to abnormal vs. normal regadenoson stress CMRs. Kaplan-Meier curves in Panel b demonstrate that cumulative incidence estimate of the composite endpoint is significantly higher in patients with abnormal vs. normal regadenoson stress CMRs.
Regadenoson is as efficacious as adenosine for inducing coronary vasodilation [8, 12, 13, 18]. Of the four known adenosine receptor subtypes (A1, A2A, A2B, and A3), activation of the A1 adenosine receptor accounts for the negative chronotropic and dromotropic effects of adenosine, while A2A is the predominant receptor subtype responsible for coronary blood flow regulation [19]. As a selective A2A receptor agonist, regadenoson has more than 13-fold lower affinity for the A1 receptor than for the A2A receptor [20], which explains its lack of super-sensitivity and fewer negative chronotropic and dromotropic effects compared with adenosine.

Our prognostic findings demonstrate, for the first time, the efficacy of regadenoson stress CMRs to identify patients at a higher risk for major adverse cardiovascular events. In many institutions, dobutamine stress echocardiography is used as the non-invasive technique of choice for the routine surveillance of heart transplant recipients. In a large study of 497 consecutive heart transplant recipients, ischemia on dobutamine stress echocardiography was not associated with a composite outcome of death, coronary revascularization, myocardial infarction, and retransplantation [21]. Our findings highlight a potential role for regadenoson stress CMR as a non-invasive modality for the detection of CAV and for the risk stratification of heart transplant recipients.

Our study is limited by the single-center, retrospective design, relatively short follow up and a small number of events. We excluded patients with chronic kidney disease (estimated glomerular filtration rate < 30 mL/min/1.73 m²). We do not have data on the presence and extent of CAV. However, our study is the first to demonstrate the safety and the prognostic value of regadenoson stress CMR in heart transplant recipients and is the largest study of the safety of regadenoson in these patients. Regardless, we cannot exclude the possibility of adverse effects that occur infrequently (i.e., < 2% incidence). Our findings provide the preliminary data necessary to support a larger, prospective, preferably multi-center, investigation on the utility of regadenoson stress CMR in heart transplant recipients and its comparison with other imaging modalities such as dobutamine stress echocardiography and computed tomography imaging.

Conclusions

Regadenoson stress CMR is safe and well tolerated in heart transplant recipients, with no incidence of sinus node dysfunction or high-degree atrioventricular block, including in the first two years after heart transplantation. An abnormal regadenoson stress CMR identifies heart transplant recipients at a higher risk for major adverse cardiovascular events.

Abbreviations

CAV: Coronary allograft vasculopathy; CMR: Cardiovascular magnetic resonance imaging; ECG: Electrocardiogram; IQR: Interquartile range; LGE: Late gadolinium enhancement; LV: Left ventricle/left ventricular; SPECT: Single-photon emission computed tomography

Acknowledgements

None.

Funding

Mehmet Akçakaya was supported by National Institutes of Health grant R01HL114140. Chetan Shenoy was supported by National Institutes of Health grant K23HL132011. University of Minnesota Clinical and Translational Science Institute KL2 Scholars Career Development Program Award (National Institutes of Health grant KL2TR000113-03) and National Institutes of Health grant UL1TR000114.

Availability of data and materials

Not applicable.

Authors’ contributions

FK made substantial contributions to the acquisition and interpretation of data for the work and to drafting the manuscript. PSN, AH, KAC, OO, CMM, MA and AF-F made substantial contributions to the interpretation of data for the work and to revising it critically for important intellectual content. LZ made substantial contributions to the analysis and interpretation of data for the work and to revising it critically for important intellectual content. CS made substantial contributions to the conception and design of the work; the acquisition, analysis, and interpretation of data for the work and to drafting the work and revising it critically for important intellectual content. All authors provided final approval of the version to be published.

Ethics approval and consent to participate

The study was approved by University of Minnesota’s Institutional Review Board with a waiver of informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Cardiovascular Division, Department of Medicine, University of Minnesota Medical Center, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA. 2 Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN, USA. 3 University of Minnesota Medical School, Minneapolis, MN, USA. 4 Department of Electrical and Computer Engineering and Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, USA. 5 Division of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.

Received: 6 April 2018 Accepted: 4 December 2018

Published online: 24 January 2019

References

1. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation Report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1158–69.

2. Wilson RF, Christensen BV, Olivari MT, Simon A, White CW, Laxson DD. Evidence for structural sympathetic reinnervation after orthotopic heart transplantation in humans. Circulation. 1991;83:1210–21.

3. Awad M, Cerz LS, Hou M, Golshani SS, Golche M, De Roberts M, Kittleson M, Patel J, Azabul B, Kansod F, et al. Early denervation and later Reinnervation of the heart following cardiac transplantation: a review. J Am Heart Assoc. 2016;5.

4. Estep JD, Shah DJ, Naguwa SF, Mahmarian JJ, Torre-Amione G, Zoghbi WA. The role of multimodality cardiac imaging in the transplanted heart. JACC Cardiovasc Imaging. 2009;2:1126–40.
5. Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACC Cardiovasc Imaging. 2013;6:613–23.

6. Ellenbogen KA, Thames MD, DiMarco JP, Schild H, Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation. 1990;81:821–8.

7. Al-Mallah MH, Arida M, Garcia-Sayan E, Assal C, Zegarra GT, Czerska B, Ananthasubramaniam K. Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: a single center experience of 102 transplant patients. Int J Cardiovasc Imaging. 2011;27:1105–11.

8. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Liu H, Mahmadian JJ, Olmsted A, Underwood SR, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–58.

9. AlJaroudi WA, Alraies MC, Cerqueira MD, Jaber WA. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response. Eur J Nucl Med Mol Imaging. 2013;40:341–8.

10. Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE. Safety and tolerability of regadenoson CMR. Eur Heart J Cardiovasc Imaging. 2014;15:753–60.

11. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan multicenter trial registry. J Am Coll Cardiol. 1994;23:884–9.

12. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmadian JJ. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;46:2069–75.

13. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators A-MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008;1:307–16.

14. Huang H, Niljar PS, Misalek J, Blaes A, Deng X, Shah DN, Kazmirczak F, Klem L, Farzaneh-Far A, Sehony C. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017;19:34.

15. Dandekar VK, Baum LA, Ertel AW, Dickenson C, Gonzalez RC, Farzaneh-Far A. Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 tesla. J Cardiovasc Magn Reson. 2014;16:24.

16. Cavalcante JL, Barboza J, Ananthasubramaniam K. Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients. J Nucl Cardiol. 2011;18:628–33.

17. Anderson TJ, Ryan TJ Jr, Mudge GH, Sellin AP, Ganz P, Yeung AC. Sinusoidal and anteroventricular block caused by intracoronary infusion of adenosine early after heart transplantation. J Heart Lung Transplant. 1993;12:522–4.

18. Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE. Regadenoson and adenosine are equivalent vasodilators and are superior to dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013;15:85.

19. Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–30.

20. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzen E, Palle V, Zablocki JA, Blackburn B, Belardinelli L. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001;298:209–18.

21. Chirakanjanakorn S, Starling RC, Popovic ZB, Griffin BP, Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: diagnostic accuracy and predictors of outcomes. J Heart Lung Transplant. 2015;34:70–7.